<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03535974</url>
  </required_header>
  <id_info>
    <org_study_id>TiroNod</org_study_id>
    <nct_id>NCT03535974</nct_id>
  </id_info>
  <brief_title>Efficacy of a Spirulina Supplement for Amelioration of Benign ThYroid Nodules</brief_title>
  <acronym>ESSAY</acronym>
  <official_title>Evaluation of the Efficacy of a Supplement With Spirulina for Amelioration of Benign Thyroid Nodules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundatia Bio-Forum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundatia Bio-Forum</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial with a double-blind, placebo-controlled, crossover design; enrolls
      approximately 30 euthyroid patients with benign thyroid nodules, who will receive for 6 weeks
      a spirulina-based supplement, and for another 6 weeks placebo. Thyroid ecography will be
      performed three times for each patient, and blood tests including TSH, free T4, free T3 and
      ceruloplasmin/Copper will also be performed 3 times for each patient. It is expected that a
      decrease in the thyroid nodules occurs with the supplement administration. Compared with
      placebo there will be a decrease of at least 20% in the volume or the largest diameter of the
      nodules during the 6-week administration of the supplement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical trial with double-blind, placebo-controlled, crossover design; enrolls approximately
      30 euthyroid patients with benign thyroid nodules, who will receive for 6 weeks a
      spirulina-based supplement, and for another 6 weeks placebo.

        -  The sequence of administration supplement - placebo is unknown to the doctor or the
           patients

        -  The supplement and placebo are placed in identical capsules and vials by DVR Pharm

        -  The respective capsules are administered twice a day Thyroid ecography will be performed
           three times for each patient, and blood tests including TSH, free T4, free T3 and
           ceruloplasmin/Copper will also be performed 3 times for each patient.

        -  Echography and blood tests will be performed for each patient initially, after 6 weeks,
           and after 12 weeks It is expected that a decrease in the thyroid nodules occurs with the
           supplement administration.

        -  there will be a direct comparison of the nodules dimensions on the ecographic
           examinations, in millimeters, and of the blood levels of the molecules which reflect
           thyroid function
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2018</start_date>
  <completion_date type="Actual">December 21, 2018</completion_date>
  <primary_completion_date type="Actual">December 20, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Area of Thyroid Nodules</measure>
    <time_frame>after 6 weeks of administration of the supplement and placebo</time_frame>
    <description>Size of the thyroid nodules is measured by ultrasound, two perpendicular diameters, same incidence and operator at V1 and V2 Area of nodules is calculated as the product of the two diameters</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Benign Thyroid Nodule</condition>
  <arm_group>
    <arm_group_label>Preparation with Spirulina</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 weeks bid Preparation with Spirulina</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6 weeks bid Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Preparation with Spirulina</intervention_name>
    <description>Preparation with Spirulina to ameliorate the size of benign thyroid nodules</description>
    <arm_group_label>Preparation with Spirulina</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administration for 6 weeks bid</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  euthyroid adults (normal TSH)

          -  no criteria for malignancy is present (size, fine needle aspiration, lymph nodules)

          -  no other medication/supplement administered for thyroid, no steroids, beta-blocker

        Exclusion Criteria:

          -  suspicion of malignancy / shown

          -  autoimmune disease

          -  abnormal thyroid function

          -  Wilson disease

          -  contraception with intrauterine device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corin Badiu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institutul Parhon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fundatia Bio-Forum</name>
      <address>
        <city>Bucharest</city>
        <state>Bucuresti</state>
        <zip>040245</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <reference>
    <citation>Stancioiu F, Mihai D, Papadakis GZ, Tsatsakis A, Spandidos DA, Badiu C. Treatment for benign thyroid nodules with a combination of natural extracts. Mol Med Rep. 2019 Sep;20(3):2332-2338. doi: 10.3892/mmr.2019.10453. Epub 2019 Jul 1.</citation>
    <PMID>31322200</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 2, 2018</study_first_submitted>
  <study_first_submitted_qc>May 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2018</study_first_posted>
  <results_first_submitted>February 6, 2020</results_first_submitted>
  <results_first_submitted_qc>May 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 19, 2020</results_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Nodule</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 3, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT03535974/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 3, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT03535974/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sequence AI-P: Active Ingredient (Spirulina) Then Placebo</title>
          <description>Patients in this sequence first received 6 weeks the Active Ingredient (Spirulina) bid, and afterwards 6 weeks Placebo bid</description>
        </group>
        <group group_id="P2">
          <title>Sequence P-AI: Placebo Then Active Ingredient (Spirulina)</title>
          <description>Placebo administration for 6 weeks bid; afterwards Active Ingredient (Spirulina) for 6 weeks bid</description>
        </group>
        <group group_id="P3">
          <title>Sequence AI-AI (Active Ingredient, Then Active Ingredient)</title>
          <description>Patients receive Active Ingredient (AI) for 6 weeks bid, and afterwards Active Ingredient (AI) for 6 weeks bid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention Weeks 0-6 (V1-V2)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention Weeks 6-12 (V2-V3)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>For the primary outcome we compared the effect of the AI vs P after the initial 6 weeks of the study (V1-V2). For this we combined the AI-AI sequence and AI-P sequence in one arm, and compared with the P-AI sequence arm.</population>
      <group_list>
        <group group_id="B1">
          <title>AI-P Sequence (12)</title>
          <description>Participants who received AI initially (first six weeks, V1 and V2) and P afterwards</description>
        </group>
        <group group_id="B2">
          <title>P-AI Sequence (17)</title>
          <description>Participants who received placebo (P) initially (first six weeks, V1 and V2) and AI afterwards</description>
        </group>
        <group group_id="B3">
          <title>AI-AI Sequence (5)</title>
          <description>Participants who received AI initially (first six weeks, V1 and V2) and AI afterwards</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.58" spread="7.03"/>
                    <measurement group_id="B2" value="52.12" spread="15.26"/>
                    <measurement group_id="B3" value="52.8" spread="15"/>
                    <measurement group_id="B4" value="53.44" spread="12.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surface of Thyroid Nodules</title>
          <description>Surface of thyroid nodules in cm^2</description>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.18" spread="3.45"/>
                    <measurement group_id="B2" value="4.298" spread="3.01"/>
                    <measurement group_id="B3" value="5.18" spread="3.4"/>
                    <measurement group_id="B4" value="4.387" spread="3.139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Area of Thyroid Nodules</title>
        <description>Size of the thyroid nodules is measured by ultrasound, two perpendicular diameters, same incidence and operator at V1 and V2 Area of nodules is calculated as the product of the two diameters</description>
        <time_frame>after 6 weeks of administration of the supplement and placebo</time_frame>
        <population>Effects of AI vs P between the two arms is calculated after the first 6 weeks (V1-V2, AI vs P). After 12 weeks (V1-V3) patients in each arm/sequence receive the same treatment in a different sequence (AI+P; vs P+AI) and no difference is expected.
A second outcome compares results of all administrations of 6 weeks each of AI (39) and P (29)</population>
        <group_list>
          <group group_id="O1">
            <title>Preparation With Spirulina</title>
            <description>6 weeks bid Preparation with Spirulina
Preparation with Spirulina: Preparation with Spirulina to ameliorate the size of benign thyroid nodules decrease of 19.88% (mean) +/- 15.55 (SD)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>6 weeks bid Placebo
Placebo: Placebo administration for 6 weeks bid decrease of 9.21% (mean) +/- 14.29 (SD)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Area of Thyroid Nodules</title>
          <description>Size of the thyroid nodules is measured by ultrasound, two perpendicular diameters, same incidence and operator at V1 and V2 Area of nodules is calculated as the product of the two diameters</description>
          <population>Effects of AI vs P between the two arms is calculated after the first 6 weeks (V1-V2, AI vs P). After 12 weeks (V1-V3) patients in each arm/sequence receive the same treatment in a different sequence (AI+P; vs P+AI) and no difference is expected.
A second outcome compares results of all administrations of 6 weeks each of AI (39) and P (29)</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.98" spread="15.55"/>
                    <measurement group_id="O2" value="-9.31" spread="14.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>10.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.122</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Change in Nodule Areas, All Administrations of 6 Weeks Each (n=68), AI (n=39) Versus P (n=29)</title>
        <description>Mean modification in the area of the nodules in cm^2, calculated as the difference between the initial and final nodule area after 6 weeks of administration of either AI (total 39 administrations) or P (total 29 administrations), and standard deviation</description>
        <time_frame>after 12 weeks of administration of the supplement and placebo</time_frame>
        <population>The total number (instances) of 6 weeks administrations of either AI (n=39) or P (n=29)</population>
        <group_list>
          <group group_id="O1">
            <title>All AI Administrations (n=39)</title>
            <description>Number of all 6 weeks administrations of AI in all 34 patients and all sequences (AI-P, AI-AI, and P-AI)</description>
          </group>
          <group group_id="O2">
            <title>All P Administrations (n=29)</title>
            <description>Number of all 6 weeks administrations of P in all 34 patients and all sequences (AI-P and P-AI)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Nodule Areas, All Administrations of 6 Weeks Each (n=68), AI (n=39) Versus P (n=29)</title>
          <description>Mean modification in the area of the nodules in cm^2, calculated as the difference between the initial and final nodule area after 6 weeks of administration of either AI (total 39 administrations) or P (total 29 administrations), and standard deviation</description>
          <population>The total number (instances) of 6 weeks administrations of either AI (n=39) or P (n=29)</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.611" spread="0.933"/>
                    <measurement group_id="O2" value="0.178" spread="0.515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>One patient who was on multiple medications at enrollment developed a generalized skin eruption with moderate prurit after a few days with the study substance; she interrupted the administration after talking with the investigator and afterwards it was revealed that she was taking placebo All participants who completed the study (n=34) received the AI (active ingredient) and 5 patients out of the 34 (n=29) received the AI-AI sequence, so that only 29 patients received placebo (P)</desc>
      <group_list>
        <group group_id="E1">
          <title>Preparation With Spirulina</title>
          <description>6 weeks bid Preparation with Spirulina
Preparation with Spirulina: Preparation with Spirulina to ameliorate the size of benign thyroid nodules
0 adverse reactions</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>6 weeks bid Placebo
Placebo: Placebo administration for 6 weeks bid
One patient had a severe allergic reaction while she was on placebo and multiple other medications and withdrew from the study</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>allergic reaction while on placebo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>allergic reaction while on placebo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Felician Stancioiu</name_or_title>
      <organization>Fundatia Bio-Forum</organization>
      <phone>+40727500402</phone>
      <email>felicians11@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

